PhotoniCare’s OtoSight Demonstrates More Accurate Diagnosis and a 50 Percent Reduction in Antibiotic Usage for Pediatric Ear Infections in Large Randomized Controlled Trial
DURHAM, N.C. and GRAND RAPIDS, Mich., May 19, 2025 (GLOBE NEWSWIRE) — PhotoniCare Inc., a medical device company dedicated to delivering innovation to frontline care that demonstrably enhances patient outcomes, is pleased to announce its progress in the diagnosis and treatment of pediatric ear infections that affect more than 80 percent of children by age three, account for millions of visits to the pediatrician each year, and are the leading cause of antibiotic use in children. The interim results from the OTO-MATIC randomized controlled trial (RCT) demonstrate PhotoniCare’s OtoSight™ Middle Ear Scope significantly reduces the number of antibiotic prescriptions written for pediatric patients presenting to a primary care office with ear-related complaints as well as a shift toward more singular treatment decisions, reducing reliance on combination therapies. The multicenter, real-world effectiveness study showed a 50 percent reduction in the odds of antibiotic prescribing when clinicians used PhotoniCare’s Optical Coherence Tomography (OCT) otoscope, compared to the standard of care (SOC) with a traditional otoscope.
